Does the media refer more to NRIX or FBRX?

In the previous week, Nurix Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 12 mentions for Nurix Therapeutics and 6 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.73 beat Nurix Therapeutics' score of 0.51 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or FBRX?

In the previous week, Forte Biosciences had 1 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 6 mentions for Forte Biosciences and 5 mentions for Agios Pharmaceuticals. Forte Biosciences' average media sentiment score of 0.73 beat Agios Pharmaceuticals' score of -0.05 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VCEL or FBRX more profitable?

Vericel has a net margin of 7.35% compared to Forte Biosciences' net margin of 0.00%. Vericel's return on equity of 6.41% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% Forte Biosciences N/A -106.17% -85.50%

Does the media favor VCEL or FBRX?

In the previous week, Vericel had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 9 mentions for Vericel and 6 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.73 beat Vericel's score of 0.48 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, FBRX or BHVN?

Forte Biosciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is FBRX or BHVN more profitable?

Forte Biosciences' return on equity of -106.17% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Biohaven N/A -866.46% -137.99%

Does the media prefer FBRX or BHVN?

In the previous week, Forte Biosciences had 5 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Forte Biosciences and 1 mentions for Biohaven. Biohaven's average media sentiment score of 0.90 beat Forte Biosciences' score of 0.73 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PHVS or FBRX?

Pharvaris is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is PHVS or FBRX more profitable?

Pharvaris' return on equity of -67.56% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Forte Biosciences N/A -106.17% -85.50%

Does the media favor PHVS or FBRX?

In the previous week, Pharvaris and Pharvaris both had 6 articles in the media. Pharvaris' average media sentiment score of 0.93 beat Forte Biosciences' score of 0.73 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Forte Biosciences (FBRX) Competitors

$48.86 +3.87 (+8.60%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$48.78 -0.08 (-0.16%)

As of 07/17/2026 07:47 PM Eastern

Compare

FBRX vs. NRIX, AGIO, VCEL, BHVN, and PHVS

Should you buy Forte Biosciences stock or one of its competitors? MarketBeat compares Forte Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forte Biosciences include Nurix Therapeutics (NRIX), Agios Pharmaceuticals (AGIO), Vericel (VCEL), Biohaven (BHVN), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

How does Forte Biosciences compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Forte Biosciences (NASDAQ:FBRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, suggesting that its stock price is 185% more volatile than the broader market.

Forte Biosciences has lower revenue, but higher earnings than Nurix Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	65.26	-$264.46M	-$3.45	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Nurix Therapeutics presently has a consensus target price of $34.08, suggesting a potential upside of 47.39%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 37.13%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Forte Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Forte Biosciences	N/A	-106.17%	-85.50%

In the previous week, Nurix Therapeutics had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 12 mentions for Nurix Therapeutics and 6 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.73 beat Nurix Therapeutics' score of 0.51 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.6% of Forte Biosciences shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nurix Therapeutics beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Forte Biosciences (NASDAQ:FBRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Forte Biosciences had 1 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 6 mentions for Forte Biosciences and 5 mentions for Agios Pharmaceuticals. Forte Biosciences' average media sentiment score of 0.73 beat Agios Pharmaceuticals' score of -0.05 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forte Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, suggesting that its stock price is 185% more volatile than the broader market.

Forte Biosciences has lower revenue, but higher earnings than Agios Pharmaceuticals. Forte Biosciences is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	43.60	-$412.78M	-$7.25	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Agios Pharmaceuticals presently has a consensus price target of $42.56, suggesting a potential upside of 7.44%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 37.13%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Forte Biosciences has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Forte Biosciences	N/A	-106.17%	-85.50%

77.6% of Forte Biosciences shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Forte Biosciences beats Agios Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Vericel?

Vericel (NASDAQ:VCEL) and Forte Biosciences (NASDAQ:FBRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

77.6% of Forte Biosciences shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vericel has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$292.09M	8.15	$16.52M	$0.42	111.05
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Vericel presently has a consensus price target of $55.50, suggesting a potential upside of 19.00%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 37.13%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vericel has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, suggesting that its share price is 185% more volatile than the broader market.

In the previous week, Vericel had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 9 mentions for Vericel and 6 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.73 beat Vericel's score of 0.48 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forte Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a net margin of 7.35% compared to Forte Biosciences' net margin of 0.00%. Vericel's return on equity of 6.41% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Forte Biosciences	N/A	-106.17%	-85.50%

Summary

Vericel beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

How does Forte Biosciences compare to Biohaven?

Forte Biosciences (NASDAQ:FBRX) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Forte Biosciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Forte Biosciences presently has a consensus price target of $67.00, indicating a potential upside of 37.13%. Biohaven has a consensus price target of $21.63, indicating a potential upside of 39.93%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

In the previous week, Forte Biosciences had 5 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Forte Biosciences and 1 mentions for Biohaven. Biohaven's average media sentiment score of 0.90 beat Forte Biosciences' score of 0.73 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forte Biosciences has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Forte Biosciences' return on equity of -106.17% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Biohaven	N/A	-866.46%	-137.99%

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biohaven beats Forte Biosciences on 8 of the 14 factors compared between the two stocks.

How does Forte Biosciences compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Forte Biosciences (NASDAQ:FBRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Pharvaris presently has a consensus price target of $50.08, suggesting a potential upside of 43.34%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 37.13%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharvaris is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Pharvaris is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

In the previous week, Pharvaris and Pharvaris both had 6 articles in the media. Pharvaris' average media sentiment score of 0.93 beat Forte Biosciences' score of 0.73 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.6% of Forte Biosciences shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pharvaris' return on equity of -67.56% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Forte Biosciences	N/A	-106.17%	-85.50%

Pharvaris has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market.

Summary

Pharvaris beats Forte Biosciences on 9 of the 13 factors compared between the two stocks.

Get Forte Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBRX vs. The Competition

Export

Metric	Forte Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$678.47M	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-10.53	21.03	27.25	23.92
Price / Sales	N/A	167.28	513.66	89.44
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	10.37	8.26	10.69	6.18
Net Income	-$69.38M	$23.83M	$3.59B	$332.29M
7 Day Performance	11.25%	-3.47%	-2.20%	-2.05%
1 Month Performance	173.73%	2.69%	1.63%	-2.18%
1 Year Performance	379.96%	45.93%	25.64%	17.67%

Forte Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBRX Forte Biosciences	2.22 of 5 stars	$48.86 +8.6%	$67.00 +37.1%	+380.0%	$678.47M	N/A	N/A	5	Gap Down
NRIX Nurix Therapeutics	3.5906 of 5 stars	$22.98 +1.2%	$34.08 +48.3%	+106.2%	$2.38B	$83.98M	N/A	300	Analyst Revision
AGIO Agios Pharmaceuticals	1.3527 of 5 stars	$39.92 -1.6%	$42.56 +6.6%	-1.0%	$2.37B	$66.05M	N/A	390	Analyst Revision
VCEL Vericel	3.5753 of 5 stars	$46.09 -2.9%	$52.50 +13.9%	+32.0%	$2.35B	$276.26M	109.74	300	News Coverage Positive News Analyst Forecast
BHVN Biohaven	3.6829 of 5 stars	$14.98 -1.3%	$21.63 +44.4%	+10.1%	$2.26B	N/A	N/A	239

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBRX) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forte Biosciences (FBRX) Competitors

FBRX vs. NRIX, AGIO, VCEL, BHVN, and PHVS

How does Forte Biosciences compare to Nurix Therapeutics?

Summary

How does Forte Biosciences compare to Agios Pharmaceuticals?

Summary

How does Forte Biosciences compare to Vericel?

Summary

How does Forte Biosciences compare to Biohaven?

Summary

How does Forte Biosciences compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forte Biosciences (FBRX) Competitors

FBRX vs. NRIX, AGIO, VCEL, BHVN, and PHVS

How does Forte Biosciences compare to Nurix Therapeutics?

Which has more risk & volatility, NRIX or FBRX?

Which has better earnings & valuation, NRIX or FBRX?

Do analysts recommend NRIX or FBRX?

Is NRIX or FBRX more profitable?

Does the media refer more to NRIX or FBRX?

Do insiders and institutionals hold more shares of NRIX or FBRX?

Summary

How does Forte Biosciences compare to Agios Pharmaceuticals?

Does the media favor AGIO or FBRX?

Which has more volatility & risk, AGIO or FBRX?

Which has preferable earnings & valuation, AGIO or FBRX?

Do analysts rate AGIO or FBRX?

Is AGIO or FBRX more profitable?

Do insiders and institutionals believe in AGIO or FBRX?

Summary

How does Forte Biosciences compare to Vericel?

Do institutionals and insiders believe in VCEL or FBRX?

Which has higher valuation and earnings, VCEL or FBRX?

Do analysts rate VCEL or FBRX?

Which has more volatility and risk, VCEL or FBRX?

Does the media favor VCEL or FBRX?

Is VCEL or FBRX more profitable?

Summary

How does Forte Biosciences compare to Biohaven?

Which has higher valuation and earnings, FBRX or BHVN?

Do analysts prefer FBRX or BHVN?

Does the media prefer FBRX or BHVN?

Which has more volatility & risk, FBRX or BHVN?

Is FBRX or BHVN more profitable?

Do insiders & institutionals believe in FBRX or BHVN?

Summary

How does Forte Biosciences compare to Pharvaris?

Do analysts rate PHVS or FBRX?

Which has better earnings and valuation, PHVS or FBRX?

Does the media favor PHVS or FBRX?

Do institutionals & insiders hold more shares of PHVS or FBRX?

Is PHVS or FBRX more profitable?

Which has more risk and volatility, PHVS or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX vs. The Competition

Forte Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools